Keryx’s shares rally on new orphan drug title for perifosine

Keryx Biopharmaceuticals says that its experimental late-stage cancer drug perifosine won its second orphan drug classification from the FDA, helping fuel a rally in its share price. Already dubbed an orphan drug for colorectal cancer, the developer says that regulators added neuroblastoma to the special category of drugs, which is reserved for therapies aimed at relatively small populations of patients. Keryx (KERX) has high hopes for perifosine, which is being studied in a variety of...